Notice of Correction for PAR-22-088 Biomedical Research Facilities (C06 Clinical Trial Not Allowed)
Notice Number:
NOT-OD-22-078

Key Dates

Release Date:

February 18, 2022

Related Announcements

  • PAR-22-088 Biomedical Research Facilities (C06 Clinical Trial Not Allowed)
  • February 03, 2022- Notice of Correction for PAR-22-088. See Notice NOT-OD-22-072.
  • January 21, 2022- Notice of Pre-Application Webinar for PAR-22-088. See Notice NOT-OD-22-060

Issued by

Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)

Purpose

This Notice alerts applicants to an updated submission due date and to additional instructions for resubmissions that were missing from the original Funding Opportunity Announcement. Applicants who are submitting a resubmission (A1) application must include a one-page introduction addressing comments raised in the previous scientific review. The introduction must be placed in a separate file named Introduction.pdf under Other Attachments on the Other Project Information Form.

Originally Published Version:

Application Due Dates

Key Dates

Posted Date

January 4, 2022

Open Date (Earliest Submission Date)

February 15, 2022

Letter of Intent Due Date(s)

February 15, 2022

New

March 15, 2022

Renewal / Resubmission / Revision (as allowed)

March 15, 2022

Expiration Date

March 16, 2022

...

Section IV. Application and Submission Information

...

SF424(R&R) Other Project Information

Other Attachments

...

7) Institutional Support Letter (required). A letter from a high-ranking institutional official (e.g., Dean, Provost, President) indicating institutional support for the research activities to be conducted in the new facility and to document that it will be used as proposed. The letter must be co-signed by an institutional Signing Official. This letter should include plans to support such expenses as future operating and maintenance costs, staff salaries, and user training (if needed).

8) Certification of Title to Site (required): Applicants must include a legal opinion describing the interest the applicant institution has in the performance site. The legal opinion should describe any mortgages or other foreclosable liens on the property, including the principal amount of the mortgage (and rate of interest); the dates of the mortgage; the terms and conditions of repayment; the appraised value of the property; and any provisions designed to protect the Federal interest in the property. The facility must be utilized for biomedical research purposes for which it was approved for at least 20 years beginning on the date of beneficial occupancy of the space. Any lease agreement must cover a time period sufficient for the usage requirement and be a minimum of 20 years in length from the completion of the facility.

9) Support Letter (optional): A maximum of seven optional support letters may be attached. Attach the support letters in a single file; name the attachment Support Letters.

 

Corrected Version (changes are shown below in italics and underlined):

 

Application Due Dates

Key Dates 

Posted Date

January 4, 2022

Open Date (Earliest Submission Date)

February 15, 2022

Letter of Intent Due Date(s)

February 15, 2022

New

March 25, 2022

Renewal / Resubmission / Revision (as allowed)

March 25, 2022

Expiration Date

March 26, 2022

Section IV. Application and Submission Information

SF424(R&R) Other Project Information

...

Other Attachments

7) Institutional Support Letter (required). A letter from a high-ranking institutional official (e.g., Dean, Provost, President) indicating institutional support for the research activities to be conducted in the new facility and to document that it will be used as proposed. The letter must be co-signed by an institutional Signing Official. This letter should include plans to support such expenses as future operating and maintenance costs, staff salaries, and user training (if needed).

8) Certification of Title to Site (required): Applicants must include a legal opinion describing the interest the applicant institution has in the performance site. The legal opinion should describe any mortgages or other foreclosable liens on the property, including the principal amount of the mortgage (and rate of interest); the dates of the mortgage; the terms and conditions of repayment; the appraised value of the property; and any provisions designed to protect the Federal interest in the property. The facility must be utilized for biomedical research purposes for which it was approved for at least 20 years beginning on the date of beneficial occupancy of the space. Any lease agreement must cover a time period sufficient for the usage requirement and be a minimum of 20 years in length from the completion of the facility.

9) Support Letter (optional): A maximum of seven optional support letters may be attached. Attach the support letters in a single file; name the attachment Support Letters.

10) Introduction for Resubmissions: A one-page introduction responding to the comments made by the previous scientific review group is required if and only if your application is a resubmission. Name the file Introduction.pdf. For additional information on resubmissions, please consult: https://grants.nih.gov/grants/policy/amendedapps.htm

Inquiries

Please direct all inquiries to:

Karen Duca, PhD
Office of Research Infrastructure Programs (ORIP)
Telephone: 301-435-4511
Email: karen.duca@nih.gov

C. Ashley Barnes, PhD
Office of Research Infrastructure Programs (ORIP)
Telephone: 301-435-0783
Email: ashley.barnes@nih.gov